{"entity":{"id":"paper-mlsg15-mogamulizumab-atll-bjh-2015","kind":"paper","name":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","aka":["Ishida 2015"],"tldr":"Adding mogamulizumab to intensive chemotherapy for newly diagnosed adult T-cell leukaemia raised the complete remission rate from 33 to 52 per cent, with more side effects.","summary":"A multicentre randomised phase 2 study (NCT01173887) of mLSG15, a dose-intensified chemotherapy, with or without mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma, assigned 1:1. The primary endpoint was the complete response rate; secondary endpoints included overall response and safety.","asOf":"2026-11-03","links":[{"label":"British Journal of Haematology 2015","url":"https://doi.org/10.1111/bjh.13338"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/25733162/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/25733162"}],"tags":["lymphoma-evidence-entities"],"related":[],"cancers":["adult-t-cell-leukaemia-lymphoma"],"sections":[],"technologies":[],"targets":["ccr4"],"drugs":["mogamulizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["mlsg15-mogamulizumab-atll","jcog9801"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"British Journal of Haematology","year":2015,"doi":"10.1111/bjh.13338","pmid":"25733162","authors":"Ishida T, Jo T, Takemoto S, et al.","paperType":"rct","findings":["Complete response was 52 per cent (95 per cent confidence interval 33 to 71) with mLSG15 plus mogamulizumab (29 patients) and 33 per cent (16 to 55) with mLSG15 alone (24 patients).","Overall response was 86 and 75 per cent respectively.","Grade 3 or worse anaemia, thrombocytopenia, lymphopenia, leucopenia and decreased appetite were at least 10 percentage points more frequent with the combination.","Skin disorders, cytomegalovirus infection, fever, hyperglycaemia and interstitial lung disease were observed only in the combination arm."],"whatItMeans":"The randomised evidence for adding mogamulizumab to first-line chemotherapy in aggressive adult T-cell leukaemia/lymphoma: more complete remissions, more toxicity, and no survival comparison.","caveats":["Phase 2 with 53 patients; complete response, not survival, was the endpoint.","The registry records 44 enrolled; the report analyses 53."],"participants":53},"route":"/key-papers/paper-mlsg15-mogamulizumab-atll-bjh-2015/","neighbours":{"cancer":[{"id":"adult-t-cell-leukaemia-lymphoma","kind":"cancer","name":"Adult T-cell leukaemia/lymphoma","route":"/cancers/adult-t-cell-leukaemia-lymphoma/"}],"target":[{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/"}],"drug":[{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"}],"trial":[{"id":"jcog9801","kind":"trial","name":"JCOG9801","route":"/trials/jcog9801/"},{"id":"mlsg15-mogamulizumab-atll","kind":"trial","name":"mLSG15 with or without mogamulizumab","route":"/trials/mlsg15-mogamulizumab-atll/"}]}}